Phaseline

Targets › EBNA1

EBNA1: drug programs, companies and trials

5 programs from 4 companies in 7 trials: 6 Phase 1, 1 Phase 2; Oncology, Infectious disease; next expected readout Mar 2027.

Open in Phaseline: the race on EBNA1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Stanford UniversityVK-2019
EBNA1 DNA binding inhibitor
EBNA1Phase 2Nasopharyngeal CancerJun 2027
Baylor College of MedicineEBV-specific T cells: A (LMP, BARF1 and EBNA1 specific CTLs)
EBV-specific cytotoxic T lymphocytes targeting viral antigens LMP1, LMP2, BARF1, and EBNA1
LMP1, LMP2, BARF1, EBNA1Phase 1Hodgkin's DiseaseMar 2027
ModernaTXmRNA-1189
mRNA vaccine encoding Epstein-Barr virus antigens
EBNA1, LMP1, BZLF1Phase 1Epstein-Barr Virus Infection; Epstein-Barr VirusMay 2027
Memorial Sloan Kettering Cancer CenterIn Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes
Allogeneic EBV-specific T cells genetically modified to express CAR targeting CD19
CD19, EBNA1, EBNA2, EBNA3Phase 1Acute Lymphocytic LeukemiaSep 2027
Baylor College of MedicineMABEL CTLs
EBV-specific cytotoxic T lymphocytes targeting LMP, BARF-1 and EBNA1 viral antigens
LMP1, BARF1, EBNA1Phase 1Hodgkin DiseaseMar 2029

Conditions

Epstein-Barr Virus Infection (2) Epstein-Barr Virus (1) Acute Lymphocytic Leukemia (1) Hodgkin Disease (1) Hodgkin's Disease (1) Nasopharyngeal Cancer (1)

Modalities

other (3), mixed (1), small molecule (1)

Companies

Baylor College of Medicine (2) ModernaTX (1) Memorial Sloan Kettering Cancer Center (1) Stanford University (1)

Related targets

LMP1 (3) BARF1 (2) BZLF1 (1) CD19 (1) EBNA2 (1) EBNA3 (1) LMP2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.